C4 Therapeutics Partner Biogen Advances IRAK4 Degrader Toward Clinical Development.

C4 Therapeutics' partner Biogen has received FDA approval for the investigational new drug application (IND) for BIIB142, a degrader of IRAK4 targeting autoimmune diseases. C4T's collaboration with Biogen has progressed two development candidates, and Biogen is responsible for clinical development and commercialization. C4T is entitled to a $2 million milestone payment upon patient dosing in the BIIB142 clinical trial.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) has made significant strides in the biopharmaceutical sector with its partner Biogen receiving FDA approval for the investigational new drug (IND) application for BIIB142, a degrader of IRAK4. This approval marks a crucial milestone in the development of targeted protein degradation therapies for autoimmune diseases.

BIIB142, developed in collaboration between C4T and Biogen, aims to target IRAK4, a protein involved in the immune system's inflammatory response. The FDA's acceptance of Biogen's IND application for BIIB142 signifies the potential of this degrader to bring new treatment options to patients suffering from autoimmune diseases.

Under the terms of their strategic collaboration established in 2018, C4T has provided expertise and research services in targeted protein degradation, while Biogen has contributed scientific and drug development capabilities. The collaboration has resulted in the advancement of two development candidates, with BIIB142 being one of them.

Paige Mahaney, Ph.D., chief scientific officer of C4 Therapeutics, expressed her enthusiasm about the progress made with BIIB142, stating, "We are thrilled to see Biogen quickly advance the IRAK4 degrader that resulted from our collaboration toward the clinic in the hopes this molecule may bring a new treatment option to patients with autoimmune disease" [1].

Jane Grogan, Ph.D., head of research at Biogen, echoed this sentiment, highlighting the potential of BIIB142 and the collaborative efforts between C4T and Biogen. "I’m proud that we have advanced this program based on a cutting-edge modality for a disease with high unmet need, and we see great promise in continuing to pioneer these types of investigational approaches" [1].

As part of the collaboration, C4T is entitled to receive a $2 million milestone payment upon Biogen dosing patients in the BIIB142 clinical trial. This payment underscores the value of the collaboration and the progress made in developing BIIB142.

C4 Therapeutics' focus on targeted protein degradation science has been instrumental in advancing treatments for challenging diseases. The company's TORPEDO® platform has enabled the efficient design and optimization of small-molecule medicines to address difficult-to-treat diseases. This platform has shown promise in clinical studies, including those for cemsidomide, which demonstrated promising results in multiple myeloma treatment [2].

C4T's financial position remains strong, with $223.0 million in cash as of the end of the second quarter of 2025, providing a runway into mid-2027. The company's lead drug cemsidomide showed promising Phase 1 results, achieving an overall response rate of 40% at 75 µg dose and 50% at 100 µg dose in multiple myeloma patients [2].

The approval of BIIB142 by the FDA represents a significant advancement for C4 Therapeutics and Biogen, paving the way for potential new treatments for autoimmune diseases. This development is a testament to the power of collaboration and the potential of targeted protein degradation therapies in transforming patient outcomes.

References:
[1] https://www.stocktitan.net/news/CCCC/c4-therapeutics-highlights-recent-achievement-in-biogen-swo1f2fvzcvw.html
[2] https://www.stocktitan.net/news/CCCC/